Patents Represented by Attorney Thomas J. Wrona
-
Patent number: 8257707Abstract: Provided herein are IL-18 receptor antigen binding proteins and polynucleotides encoding the same. Expression vectors and host cells comprising the same for production of the antigen binding proteins are also provided. In addition, provided are compositions and methods for diagnosing and treating diseases mediated by IL-18 receptor.Type: GrantFiled: July 24, 2008Date of Patent: September 4, 2012Assignee: Amgen Inc.Inventors: Dirk E. Smith, John E. Sims, Jeffrey T. McGrew, Marek Z. Kubin, Duncan Cochrane, Louise Conroy
-
Patent number: 8163284Abstract: The present disclosure provides compositions and methods relating to antigen binding proteins which bind to human thymic stromal lymphopoietin (TSLP), including antibodies. In particular embodiments, the disclosure provides fully human, humanized and chimeric anti-TSLP antibodies and derivatives of such antibodies. The disclosure further provides nucleic acids encoding such antibodies and antibody fragments and derivatives, and methods of making and using such antibodies including methods of treating and preventing TSLP-related inflammatory and fibrotic disorders.Type: GrantFiled: July 18, 2011Date of Patent: April 24, 2012Assignee: Amgen Inc.Inventors: Michael R Comeau, James F Smothers, Bo-Rin P Yoon, Christopher Mehlin
-
Patent number: 8053233Abstract: A novel polypeptide that functions as an IL-18 receptor is disclosed. The receptor is multimeric and includes at least one AcPL polypeptide, or fragment thereof, and at least one IL-1Rrp1 polypeptide, or fraction thereof. The receptor binds IL-18 and finds use in inhibiting biological activities mediated by IL-18.Type: GrantFiled: March 3, 2010Date of Patent: November 8, 2011Assignee: Immunex CorporationInventors: John E. Sims, Teresa L. Born
-
Patent number: 8034343Abstract: 2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting prostaglandin synthesis and treating inflammation.Type: GrantFiled: October 22, 2009Date of Patent: October 11, 2011Assignee: Immunex CorporationInventors: Patricia Parnet, John E. Sims
-
Patent number: 7993845Abstract: The invention is directed to purified and isolated novel ACPL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.Type: GrantFiled: October 12, 2010Date of Patent: August 9, 2011Assignee: Immunex CorporationInventors: John E. Sims, Teresa L. Born
-
Patent number: 7982016Abstract: The present disclosure provides compositions and methods relating to antigen binding proteins which bind to human thymic stromal lymphopoietin (TSLP), including antibodies. In particular embodiments, the disclosure provides fully human, humanized and chimeric anti-TSLP antibodies and derivatives of such antibodies. The disclosure further provides nucleic acids encoding such antibodies and antibody fragments and derivatives, and methods of making and using such antibodies including methods of treating and preventing TSLP-related inflammatory and fibrotic disorders.Type: GrantFiled: September 8, 2008Date of Patent: July 19, 2011Assignee: Amgen Inc.Inventors: Michael R. Comeau, James F. Smothers, Bo-Rin P. Yoon, Christopher Mehlin
-
Patent number: 7973151Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.Type: GrantFiled: March 12, 2010Date of Patent: July 5, 2011Assignee: Amgen Inc.Inventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond J. Paxton
-
Patent number: 7964713Abstract: The present invention provides Thymic Stromal Lymphopoietin Receptor (TSLPR) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TSLPR polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with TSLPR polypeptides.Type: GrantFiled: June 28, 2001Date of Patent: June 21, 2011Assignee: Amgen Inc.Inventors: Christiaan M. Saris, Ming-Shi Chang
-
Patent number: 7838248Abstract: The invention is directed to purified and isolated novel ACPL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.Type: GrantFiled: September 17, 2007Date of Patent: November 23, 2010Assignee: Immunex CorporationInventors: John E. Sims, Teresa L. Born
-
Patent number: 7786271Abstract: The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.Type: GrantFiled: July 28, 2008Date of Patent: August 31, 2010Assignee: Immunex CorporationInventors: John E. Sims, Stewart D. Lyman, Hilary J. McKenna, Allison P. Armstrong
-
Patent number: 7709217Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.Type: GrantFiled: October 30, 2007Date of Patent: May 4, 2010Assignee: Immunex CorporationInventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond J. Paxton
-
Patent number: 7704945Abstract: A novel polypeptide that functions as an IL-18 receptor is disclosed. The receptor is multimeric and includes at least one AcPL polypeptide, or fragment thereof, and at least one IL-1Rrp1 polypeptide, or fraction thereof. The receptor binds IL-18 and finds use in inhibiting biological activities mediated by IL-18.Type: GrantFiled: January 29, 2007Date of Patent: April 27, 2010Assignee: Immunex CorporationInventors: John E. Sims, Teresa L. Born
-
Patent number: 7405058Abstract: The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.Type: GrantFiled: June 13, 2006Date of Patent: July 29, 2008Assignee: Immunex CorporationInventors: John E. Sims, Stewart D. Lyman, Hilary Jean McKenna, Allison P. Armstrong
-
Patent number: 7288633Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.Type: GrantFiled: July 23, 2002Date of Patent: October 30, 2007Assignee: Immunex CorporationInventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond J. Paxton
-
Patent number: 7270817Abstract: The invention is directed to purified and isolated novel ACPL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.Type: GrantFiled: February 6, 2004Date of Patent: September 18, 2007Assignee: Immunex CorporationInventors: John E. Sims, Teresa L. Born
-
Patent number: 7235238Abstract: 2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting prostaglandin synthesis and treating inflammation.Type: GrantFiled: May 28, 2004Date of Patent: June 26, 2007Assignee: Amgen Inc.Inventors: Patricia Parnet, John E. Sims